Concepts (326)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alopecia | 23 | 2020 | 31 | 9.310 |
Why?
|
| African Americans | 22 | 2020 | 1428 | 3.640 |
Why?
|
| Skin Pigmentation | 10 | 2020 | 26 | 3.590 |
Why?
|
| Scalp Dermatoses | 8 | 2021 | 18 | 3.250 |
Why?
|
| Hair | 9 | 2019 | 28 | 3.200 |
Why?
|
| Scalp | 10 | 2020 | 38 | 2.880 |
Why?
|
| Hair Preparations | 12 | 2020 | 12 | 2.840 |
Why?
|
| Alopecia Areata | 14 | 2020 | 16 | 2.750 |
Why?
|
| Cicatrix | 8 | 2020 | 38 | 2.390 |
Why?
|
| Lichen Planus | 5 | 2021 | 10 | 2.260 |
Why?
|
| Dermatology | 8 | 2020 | 163 | 1.990 |
Why?
|
| Minoxidil | 5 | 2017 | 6 | 1.830 |
Why?
|
| Hyperpigmentation | 8 | 2018 | 17 | 1.760 |
Why?
|
| Humans | 89 | 2021 | 31836 | 1.640 |
Why?
|
| Skin Diseases | 4 | 2020 | 142 | 1.620 |
Why?
|
| Dermatologic Agents | 11 | 2020 | 229 | 1.430 |
Why?
|
| Acne Vulgaris | 7 | 2019 | 96 | 1.330 |
Why?
|
| Hair Removal | 4 | 2012 | 5 | 1.290 |
Why?
|
| Ethnic Groups | 7 | 2020 | 476 | 1.280 |
Why?
|
| African Continental Ancestry Group | 7 | 2017 | 363 | 1.240 |
Why?
|
| Middle Aged | 34 | 2020 | 11824 | 1.150 |
Why?
|
| Adult | 34 | 2020 | 9327 | 1.130 |
Why?
|
| Female | 46 | 2020 | 19859 | 1.130 |
Why?
|
| Patient Satisfaction | 5 | 2016 | 240 | 1.030 |
Why?
|
| Severity of Illness Index | 14 | 2020 | 899 | 1.020 |
Why?
|
| Glucocorticoids | 5 | 2020 | 147 | 1.000 |
Why?
|
| Cultural Diversity | 3 | 2020 | 21 | 0.930 |
Why?
|
| Internship and Residency | 3 | 2020 | 306 | 0.910 |
Why?
|
| European Continental Ancestry Group | 6 | 2019 | 1169 | 0.910 |
Why?
|
| Laser Therapy | 5 | 2012 | 55 | 0.880 |
Why?
|
| Psoriasis | 3 | 2019 | 360 | 0.880 |
Why?
|
| Skin | 4 | 2019 | 210 | 0.850 |
Why?
|
| Academic Medical Centers | 3 | 2020 | 156 | 0.780 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2021 | 6 | 0.760 |
Why?
|
| Hair Diseases | 3 | 2007 | 4 | 0.760 |
Why?
|
| Photochemotherapy | 1 | 2021 | 21 | 0.740 |
Why?
|
| Dermoscopy | 1 | 2020 | 12 | 0.730 |
Why?
|
| Triamcinolone Acetonide | 1 | 2020 | 4 | 0.710 |
Why?
|
| Delusions | 1 | 2019 | 3 | 0.700 |
Why?
|
| Psychophysiologic Disorders | 1 | 2019 | 5 | 0.700 |
Why?
|
| Lasers, Solid-State | 3 | 2020 | 8 | 0.700 |
Why?
|
| Pityriasis Lichenoides | 1 | 2019 | 3 | 0.690 |
Why?
|
| Hypopigmentation | 1 | 2019 | 7 | 0.680 |
Why?
|
| Drug Therapy, Combination | 3 | 2016 | 284 | 0.680 |
Why?
|
| Socioeconomic Factors | 2 | 2019 | 420 | 0.670 |
Why?
|
| Continental Population Groups | 3 | 2020 | 236 | 0.670 |
Why?
|
| Forehead | 2 | 2019 | 13 | 0.670 |
Why?
|
| Exercise | 2 | 2016 | 663 | 0.660 |
Why?
|
| Skin Diseases, Viral | 1 | 2019 | 4 | 0.660 |
Why?
|
| Dietary Supplements | 2 | 2017 | 185 | 0.660 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 4 | 0.660 |
Why?
|
| Herpes Zoster | 1 | 2019 | 10 | 0.660 |
Why?
|
| United States | 16 | 2020 | 3925 | 0.640 |
Why?
|
| Young Adult | 11 | 2018 | 2603 | 0.630 |
Why?
|
| Radiotherapy | 1 | 2018 | 82 | 0.630 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 244 | 0.620 |
Why?
|
| Quality of Life | 7 | 2019 | 924 | 0.620 |
Why?
|
| Parabens | 1 | 2018 | 1 | 0.620 |
Why?
|
| Sulfates | 1 | 2018 | 2 | 0.620 |
Why?
|
| Barbering | 2 | 2017 | 2 | 0.600 |
Why?
|
| Hygiene | 2 | 2015 | 13 | 0.600 |
Why?
|
| Dermatitis, Atopic | 1 | 2019 | 102 | 0.600 |
Why?
|
| Treatment Outcome | 12 | 2020 | 3294 | 0.590 |
Why?
|
| Male | 28 | 2019 | 19091 | 0.580 |
Why?
|
| Adjuvants, Immunologic | 2 | 2010 | 55 | 0.580 |
Why?
|
| Occupational Exposure | 2 | 2016 | 233 | 0.580 |
Why?
|
| Vitamins | 1 | 2017 | 68 | 0.570 |
Why?
|
| Evidence-Based Medicine | 2 | 2017 | 215 | 0.550 |
Why?
|
| Health Education | 1 | 2017 | 157 | 0.550 |
Why?
|
| Keloid | 2 | 2013 | 8 | 0.550 |
Why?
|
| Skin Care | 1 | 2016 | 13 | 0.540 |
Why?
|
| Pigmentation Disorders | 2 | 2014 | 8 | 0.540 |
Why?
|
| Hispanic Americans | 4 | 2016 | 942 | 0.530 |
Why?
|
| Biological Products | 1 | 2017 | 77 | 0.530 |
Why?
|
| Adolescent | 14 | 2019 | 3511 | 0.530 |
Why?
|
| Beauty | 2 | 2013 | 5 | 0.530 |
Why?
|
| Research Design | 2 | 2017 | 310 | 0.520 |
Why?
|
| Plant Extracts | 1 | 2016 | 61 | 0.520 |
Why?
|
| Asian Continental Ancestry Group | 2 | 2014 | 108 | 0.490 |
Why?
|
| Cosmetic Techniques | 2 | 2017 | 11 | 0.490 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 214 | 0.480 |
Why?
|
| Foot Diseases | 1 | 2014 | 10 | 0.470 |
Why?
|
| Cross-Sectional Studies | 6 | 2020 | 1527 | 0.470 |
Why?
|
| Urea | 1 | 2014 | 37 | 0.470 |
Why?
|
| Lasers, Excimer | 1 | 2013 | 8 | 0.460 |
Why?
|
| Keratins, Hair-Specific | 1 | 2013 | 1 | 0.450 |
Why?
|
| Formaldehyde | 1 | 2013 | 11 | 0.450 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 607 | 0.450 |
Why?
|
| Diagnosis, Differential | 4 | 2019 | 518 | 0.430 |
Why?
|
| Lip | 1 | 2012 | 7 | 0.420 |
Why?
|
| Child | 8 | 2018 | 2425 | 0.410 |
Why?
|
| Lice Infestations | 1 | 2011 | 1 | 0.400 |
Why?
|
| Neoplasms | 1 | 2018 | 692 | 0.400 |
Why?
|
| Biopsy | 4 | 2019 | 260 | 0.390 |
Why?
|
| Health Behavior | 1 | 2013 | 231 | 0.380 |
Why?
|
| Administration, Topical | 5 | 2020 | 140 | 0.370 |
Why?
|
| Osteoma | 1 | 2010 | 1 | 0.370 |
Why?
|
| Injections, Intralesional | 3 | 2020 | 15 | 0.370 |
Why?
|
| Facial Neoplasms | 1 | 2010 | 9 | 0.370 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2019 | 504 | 0.360 |
Why?
|
| Aged | 13 | 2016 | 10288 | 0.360 |
Why?
|
| Aminoquinolines | 1 | 2010 | 16 | 0.350 |
Why?
|
| Palate | 1 | 2009 | 4 | 0.330 |
Why?
|
| Hypertrichosis | 1 | 2009 | 3 | 0.330 |
Why?
|
| Histiocytosis, Langerhans-Cell | 2 | 2008 | 5 | 0.320 |
Why?
|
| Surgical Flaps | 1 | 2009 | 72 | 0.310 |
Why?
|
| Isotretinoin | 3 | 2016 | 12 | 0.310 |
Why?
|
| Phototherapy | 3 | 2020 | 52 | 0.300 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2011 | 353 | 0.300 |
Why?
|
| Hot Temperature | 1 | 2007 | 70 | 0.300 |
Why?
|
| Photography | 3 | 2017 | 42 | 0.300 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2009 | 199 | 0.280 |
Why?
|
| Dermatitis, Seborrheic | 2 | 2017 | 4 | 0.280 |
Why?
|
| Adrenal Cortex Hormones | 4 | 2020 | 127 | 0.280 |
Why?
|
| Postoperative Complications | 1 | 2012 | 779 | 0.280 |
Why?
|
| Melanosis | 3 | 2020 | 15 | 0.270 |
Why?
|
| Cosmetics | 3 | 2019 | 11 | 0.250 |
Why?
|
| Rosacea | 2 | 2017 | 45 | 0.250 |
Why?
|
| Irritants | 1 | 2004 | 2 | 0.240 |
Why?
|
| Retrospective Studies | 4 | 2020 | 3488 | 0.240 |
Why?
|
| Sunscreening Agents | 2 | 2019 | 13 | 0.240 |
Why?
|
| Data Collection | 3 | 2017 | 180 | 0.230 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Health Care Surveys | 3 | 2015 | 186 | 0.230 |
Why?
|
| Sex Factors | 4 | 2015 | 662 | 0.230 |
Why?
|
| Age Factors | 3 | 2020 | 1187 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2003 | 49 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Administration, Oral | 2 | 2020 | 181 | 0.220 |
Why?
|
| Double-Blind Method | 4 | 2019 | 523 | 0.220 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Comorbidity | 3 | 2014 | 566 | 0.210 |
Why?
|
| Skin Ulcer | 1 | 2002 | 11 | 0.210 |
Why?
|
| Herpes Simplex | 1 | 2002 | 13 | 0.210 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 18 | 0.200 |
Why?
|
| Erythema | 1 | 2002 | 27 | 0.200 |
Why?
|
| Child, Preschool | 3 | 2014 | 1259 | 0.200 |
Why?
|
| Office Visits | 2 | 2015 | 73 | 0.200 |
Why?
|
| Aminolevulinic Acid | 1 | 2021 | 9 | 0.190 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2020 | 4 | 0.190 |
Why?
|
| Prevalence | 3 | 2019 | 979 | 0.190 |
Why?
|
| Photosensitizing Agents | 1 | 2021 | 23 | 0.190 |
Why?
|
| Case-Control Studies | 3 | 2016 | 895 | 0.190 |
Why?
|
| Injections, Intradermal | 1 | 2020 | 6 | 0.190 |
Why?
|
| Physician-Patient Relations | 2 | 2012 | 184 | 0.180 |
Why?
|
| Bibliometrics | 1 | 2020 | 11 | 0.180 |
Why?
|
| Hypochondriasis | 1 | 2019 | 1 | 0.180 |
Why?
|
| Schizophrenia, Paranoid | 1 | 2019 | 2 | 0.180 |
Why?
|
| Risk Factors | 5 | 2016 | 3851 | 0.170 |
Why?
|
| S100 Proteins | 1 | 2019 | 18 | 0.170 |
Why?
|
| Drug Compounding | 2 | 2018 | 37 | 0.170 |
Why?
|
| Publishing | 1 | 2020 | 60 | 0.170 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2019 | 28 | 0.170 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2018 | 5 | 0.160 |
Why?
|
| Methotrexate | 1 | 2019 | 64 | 0.160 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 238 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2002 | 461 | 0.160 |
Why?
|
| Dapsone | 1 | 2018 | 4 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 49 | 0.150 |
Why?
|
| North Carolina | 4 | 2016 | 1514 | 0.150 |
Why?
|
| Chronic Disease | 1 | 2019 | 400 | 0.150 |
Why?
|
| Cultural Competency | 1 | 2017 | 19 | 0.150 |
Why?
|
| Infant | 2 | 2014 | 1055 | 0.150 |
Why?
|
| Internet | 2 | 2018 | 195 | 0.150 |
Why?
|
| Administration, Cutaneous | 3 | 2015 | 116 | 0.150 |
Why?
|
| Vaccination | 1 | 2019 | 136 | 0.150 |
Why?
|
| Disease Progression | 1 | 2019 | 593 | 0.140 |
Why?
|
| Demography | 1 | 2017 | 110 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 300 | 0.140 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2009 | 103 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 835 | 0.140 |
Why?
|
| Pharmaceutical Solutions | 1 | 2016 | 1 | 0.140 |
Why?
|
| Keratolytic Agents | 3 | 2005 | 29 | 0.140 |
Why?
|
| Finasteride | 1 | 2016 | 4 | 0.140 |
Why?
|
| Mutation | 1 | 2019 | 487 | 0.140 |
Why?
|
| Cross-Cultural Comparison | 1 | 2016 | 26 | 0.140 |
Why?
|
| Off-Label Use | 1 | 2016 | 12 | 0.140 |
Why?
|
| Constipation | 1 | 2016 | 12 | 0.140 |
Why?
|
| Hydroquinones | 2 | 2014 | 6 | 0.130 |
Why?
|
| Models, Statistical | 1 | 2017 | 173 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2017 | 122 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 297 | 0.130 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 91 | 0.130 |
Why?
|
| Decision Making | 1 | 2018 | 194 | 0.130 |
Why?
|
| Facial Dermatoses | 2 | 2006 | 18 | 0.130 |
Why?
|
| Cellulitis | 1 | 2015 | 10 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 404 | 0.120 |
Why?
|
| Deafness | 1 | 2014 | 1 | 0.120 |
Why?
|
| Keratoderma, Palmoplantar | 1 | 2014 | 1 | 0.120 |
Why?
|
| Acne Keloid | 1 | 2014 | 2 | 0.120 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2014 | 22 | 0.120 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 1012 | 0.120 |
Why?
|
| Infant, Newborn | 2 | 2014 | 665 | 0.120 |
Why?
|
| Retinoids | 1 | 2014 | 41 | 0.120 |
Why?
|
| Educational Status | 2 | 2011 | 178 | 0.110 |
Why?
|
| Triamcinolone | 1 | 2013 | 11 | 0.110 |
Why?
|
| Pruritus | 1 | 2012 | 47 | 0.100 |
Why?
|
| Incidence | 2 | 2007 | 1192 | 0.100 |
Why?
|
| Sensory Receptor Cells | 1 | 2012 | 30 | 0.100 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 59 | 0.100 |
Why?
|
| Lasers, Semiconductor | 1 | 2011 | 1 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2012 | 108 | 0.100 |
Why?
|
| Caregivers | 1 | 2012 | 113 | 0.090 |
Why?
|
| Time Factors | 1 | 2016 | 2146 | 0.090 |
Why?
|
| Ointments | 1 | 2010 | 24 | 0.090 |
Why?
|
| Keratosis, Actinic | 1 | 2010 | 20 | 0.090 |
Why?
|
| Prognosis | 2 | 2004 | 1498 | 0.090 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2009 | 2 | 0.080 |
Why?
|
| Pharyngectomy | 1 | 2009 | 2 | 0.080 |
Why?
|
| Oropharynx | 1 | 2009 | 6 | 0.080 |
Why?
|
| Algorithms | 1 | 2012 | 495 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 564 | 0.080 |
Why?
|
| Sunlight | 2 | 2005 | 17 | 0.080 |
Why?
|
| Tretinoin | 2 | 2005 | 34 | 0.080 |
Why?
|
| Bone Diseases | 1 | 2008 | 18 | 0.080 |
Why?
|
| Microscopy | 1 | 2007 | 26 | 0.080 |
Why?
|
| Mexico | 1 | 2007 | 71 | 0.080 |
Why?
|
| Stress, Mechanical | 1 | 2007 | 92 | 0.070 |
Why?
|
| Patient Education as Topic | 2 | 2007 | 271 | 0.070 |
Why?
|
| Anthralin | 1 | 2007 | 2 | 0.070 |
Why?
|
| PUVA Therapy | 1 | 2007 | 22 | 0.070 |
Why?
|
| Medical Staff, Hospital | 1 | 2007 | 19 | 0.070 |
Why?
|
| Patients | 1 | 2007 | 46 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 2271 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2007 | 80 | 0.070 |
Why?
|
| Women | 1 | 2006 | 11 | 0.070 |
Why?
|
| Ornithine Decarboxylase | 1 | 2005 | 1 | 0.060 |
Why?
|
| Dermabrasion | 1 | 2004 | 2 | 0.060 |
Why?
|
| Skin Aging | 1 | 2005 | 9 | 0.060 |
Why?
|
| Cryosurgery | 1 | 2004 | 20 | 0.060 |
Why?
|
| Dinitrochlorobenzene | 1 | 2004 | 1 | 0.060 |
Why?
|
| Cyclobutanes | 1 | 2004 | 2 | 0.060 |
Why?
|
| Ultraviolet Rays | 1 | 2005 | 50 | 0.060 |
Why?
|
| Cyclopropanes | 1 | 2004 | 19 | 0.060 |
Why?
|
| Folliculitis | 1 | 2004 | 1 | 0.060 |
Why?
|
| Antigens, CD1 | 1 | 2004 | 2 | 0.060 |
Why?
|
| Sarcoidosis, Pulmonary | 1 | 2004 | 4 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 52 | 0.060 |
Why?
|
| Prednisone | 1 | 2004 | 61 | 0.060 |
Why?
|
| Inflammation | 2 | 2004 | 540 | 0.060 |
Why?
|
| Hirsutism | 1 | 2003 | 1 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2004 | 136 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 195 | 0.050 |
Why?
|
| Age Distribution | 1 | 2003 | 206 | 0.050 |
Why?
|
| Endpoint Determination | 2 | 2017 | 20 | 0.050 |
Why?
|
| Patient Selection | 1 | 2004 | 276 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 211 | 0.050 |
Why?
|
| Simplexvirus | 1 | 2002 | 3 | 0.050 |
Why?
|
| Acyclovir | 1 | 2002 | 13 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2002 | 21 | 0.050 |
Why?
|
| Immunocompromised Host | 1 | 2002 | 50 | 0.050 |
Why?
|
| Fingers | 1 | 2002 | 64 | 0.050 |
Why?
|
| Face | 1 | 2020 | 29 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2020 | 11 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 40 | 0.040 |
Why?
|
| Medicine | 1 | 2020 | 38 | 0.040 |
Why?
|
| Mutagenesis | 1 | 2019 | 33 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2020 | 80 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 57 | 0.040 |
Why?
|
| Pedigree | 1 | 2019 | 140 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 93 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 135 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 2019 | 298 | 0.040 |
Why?
|
| Nasopharyngitis | 1 | 2018 | 2 | 0.040 |
Why?
|
| Dogs | 1 | 2018 | 116 | 0.040 |
Why?
|
| Fibrosis | 1 | 2018 | 118 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2018 | 44 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 159 | 0.030 |
Why?
|
| Injections | 1 | 2015 | 64 | 0.030 |
Why?
|
| Tacrolimus | 1 | 2015 | 64 | 0.030 |
Why?
|
| Oceanic Ancestry Group | 1 | 2014 | 7 | 0.030 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2012 | 9 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2012 | 65 | 0.030 |
Why?
|
| Pain Threshold | 1 | 2012 | 92 | 0.030 |
Why?
|
| Mice | 1 | 2018 | 2476 | 0.020 |
Why?
|
| Perception | 1 | 2012 | 98 | 0.020 |
Why?
|
| Hyperandrogenism | 1 | 2010 | 2 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 351 | 0.020 |
Why?
|
| Fathers | 1 | 2010 | 12 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2010 | 3988 | 0.020 |
Why?
|
| Southeastern United States | 1 | 2010 | 79 | 0.020 |
Why?
|
| New York City | 1 | 2009 | 14 | 0.020 |
Why?
|
| Mothers | 1 | 2010 | 88 | 0.020 |
Why?
|
| Injections, Intramuscular | 1 | 2009 | 41 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 131 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 158 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 272 | 0.020 |
Why?
|
| Remission, Spontaneous | 1 | 2008 | 14 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 629 | 0.020 |
Why?
|
| Pamphlets | 1 | 2007 | 5 | 0.020 |
Why?
|
| Leisure Activities | 1 | 2007 | 13 | 0.020 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2007 | 16 | 0.020 |
Why?
|
| Knowledge | 1 | 2007 | 14 | 0.020 |
Why?
|
| Radiography | 1 | 2008 | 376 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2007 | 57 | 0.020 |
Why?
|
| Animals | 1 | 2018 | 7450 | 0.020 |
Why?
|
| Self Concept | 1 | 2006 | 42 | 0.020 |
Why?
|
| Chemexfoliation | 1 | 2004 | 2 | 0.020 |
Why?
|
| Lentigo | 1 | 2004 | 4 | 0.020 |
Why?
|
| Dicarboxylic Acids | 1 | 2004 | 7 | 0.020 |
Why?
|
| Nails | 1 | 2004 | 6 | 0.020 |
Why?
|
| Cryotherapy | 1 | 2004 | 13 | 0.020 |
Why?
|
| Helping Behavior | 1 | 2004 | 1 | 0.020 |
Why?
|
| Nursing Assessment | 1 | 2004 | 11 | 0.020 |
Why?
|
| Foundations | 1 | 2004 | 8 | 0.020 |
Why?
|
| Causality | 1 | 2004 | 37 | 0.010 |
Why?
|
| Self-Help Groups | 1 | 2004 | 10 | 0.010 |
Why?
|
| Information Services | 1 | 2004 | 15 | 0.010 |
Why?
|
| Primary Prevention | 1 | 2004 | 54 | 0.010 |
Why?
|
| Health Status | 1 | 2007 | 397 | 0.010 |
Why?
|
| Hair Follicle | 1 | 2004 | 8 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 184 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2006 | 686 | 0.010 |
Why?
|
| Injections, Subcutaneous | 1 | 2004 | 35 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 1431 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2004 | 124 | 0.010 |
Why?
|
| Drug Utilization | 1 | 2003 | 49 | 0.010 |
Why?
|
| Self Care | 1 | 2004 | 144 | 0.010 |
Why?
|
| Genotype | 1 | 2005 | 727 | 0.010 |
Why?
|
| Social Support | 1 | 2004 | 180 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2004 | 140 | 0.010 |
Why?
|
| Registries | 1 | 2004 | 295 | 0.010 |
Why?
|
| Cytokines | 1 | 2004 | 259 | 0.010 |
Why?
|
| Women's Health | 1 | 2004 | 235 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2005 | 2277 | 0.010 |
Why?
|